Opendata, web and dolomites

NIRCOThera SIGNED

Spatiotemporal, near-infrared light controlled carbon monoxide delivery for cancer immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NIRCOThera project word cloud

Explore the words cloud of the NIRCOThera project. It provides you a very rough idea of what is the project "NIRCOThera" about.

cell    unexploited    platform    angiogenesis    disorders       modulatory    protein    critical    rebr3    dependent    cardiovascular    components    plan    spatiotemporal    naturally    release    vivo    activation    avenue    precise    species    microenvironment    loaded    herein    inflammation    genes    shown    ready    effect    releasing    nir    purpose    molecule    profile    carbon    co    metastasis    combine    progression    relatively    exposure    largely    infiltrating    health    generation    treatment    dose    functionalized    stability    tumour    reported    chemotherapy    rhenium    anti    nanotubes    ultrahigh    exogeneous    reactive    human    immunomodulatory    intratumoural    clearance    corms    net4    lipid    cancer    fast    exclusively    diseases    chemotherapeutics    excretion    inflammatory    eradicate    biocompatibility    precision    immune    oxygen    bifunctional    time    realize    near    gaseous    triggered    signaling    followed    tissues    progress    toxicity    monoxide    expression    models    manner    site    chosen    body    animal    manipulate    swcnts    strategy    sites    light    molecules    walled    cells    expecting    therapeutic    sensitivity    consists    multiple    tumours    ros    conjugate    single    infrared       impart   

Project "NIRCOThera" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 183˙454.00

Map

 Project objective

Carbon monoxide (CO) is a gaseous signaling molecule naturally produced by the human body. In recent years, CO has shown its anti-inflammatory and immunomodulatory properties and thus therapeutic potential in the treatment of inflammatory disorders and cardiovascular diseases. It is promising to exploit the modulatory effect of exogeneous CO in tumour microenvironment where inflammation and angiogenesis are the critical components of tumour progression and metastasis, which is largely unexploited. For this purpose, it is key to manipulate CO exposure in a precise dose and time-controlled manner exclusively at the tumour site. Herein, we propose to develop a new CO delivery avenue, enabling controlled CO release to tumour sites with spatiotemporal precision by using near infrared light (NIR). Specifically, the strategy consists of single-walled carbon nanotubes (SWCNTs) loaded with CO releasing molecules (CORMs). We have reported the development of a SWCNTs-based bifunctional system that enables intratumoural protein delivery and NIR activation, which is ready to be applied to realize controlled CO release in vivo. We plan to conjugate [ReBr3(CO)3][NEt4]2 to SWCNTs. The rhenium complex is chosen because of its stability and non-toxicity while the lipid functionalized SWCNTs have shown biocompatibility, ultrahigh tumour uptake and relatively fast clearance and excretion from the health tissues, which impart the platform promising for in vivo application. We will evaluate the stability of the platform, followed by the NIR-triggered CO release profile and then dose- and time-dependent effect on both cancer cells and tumour-infiltrating immune cells, including the generation of reactive oxygen species (ROS) and expression of multiple genes associated with tumour progress. Furthermore, expecting increased cancer cell sensitivity to chemotherapeutics with CO treatment, we will combine the proposed strategy with current chemotherapy to eradicate tumours in animal models.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NIRCOTHERA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NIRCOTHERA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

LiverMacRegenCircuit (2020)

Elucidating the role of macrophages in liver regeneration and tissue unit formation

Read More  

MY MITOCOMPLEX (2021)

Functional relevance of mitochondrial supercomplex assembly in myeloid cells

Read More  

ICEDRAGON (2020)

Modelling of dust formation and chemistry in AGB outflows and disks

Read More